Latest Capital Raise News

Alice Queen Limited has voluntarily suspended trading of its shares on the ASX as it finalises a proposed capital raising, with an announcement expected by 5 May 2025.

BluGlass has completed a $2.3 million placement and launched a $6 million Share Purchase Plan to fund scaling of its GaN laser production, targeting high-growth sectors including quantum sensing and defense.

Anagenics Limited reported a cash outflow of $424K for Q3 2025 but maintains robust liquidity with $1.48 million in available funding, supported by a mix of secured and unsecured loans.

Sparc Technologies has successfully raised up to A$2.7 million through a share placement and a Share Purchase Plan, positioning the company to accelerate commercialisation of its graphene additive ecosparc and support its green hydrogen pilot projects.

BlinkLab Limited has raised A$7.66 million through a well-supported placement to accelerate FDA regulatory trials for its autism and ADHD diagnostic platforms, leveraging its innovative smartphone-based technology.

AdAlta Limited has announced a renounceable rights issue to raise up to $1.3 million, aiming to accelerate its ‘East to West’ cellular immunotherapy strategy and explore new strategic options.

Southern Cross Gold Consolidated Ltd has successfully arranged a C$143 million private placement, positioning the company to accelerate development of its Sunday Creek Gold-Antimony Project in Victoria, Australia.

Nanoveu Limited has successfully raised $2.3 million through a share placement to accelerate development and commercialization of its cutting-edge semiconductor, 3D visualization, and solar coating technologies.

A1 Investments & Resources Limited reported negative operating cash flows and no business activity in Q1 2025, drawing down $200,000 of a $300,000 loan as it seeks a transaction to regain ASX listing status.

Rewardle Holdings reported a strong March quarter with positive operational cash flow of $1.36 million, driven by its strategic partnership with MedTech firm CloudHolter, while progressing towards ASX relisting.

Assetora Limited has dramatically reduced its net liabilities and strengthened its balance sheet through strategic capital raises and debt conversions, while unveiling a comprehensive rebrand and leadership expansion to drive its next growth phase.

Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.